TR201904207T4 - Olgun dendritik hücrelerin hazırlanması için bileşimler. - Google Patents

Olgun dendritik hücrelerin hazırlanması için bileşimler. Download PDF

Info

Publication number
TR201904207T4
TR201904207T4 TR2019/04207T TR201904207T TR201904207T4 TR 201904207 T4 TR201904207 T4 TR 201904207T4 TR 2019/04207 T TR2019/04207 T TR 2019/04207T TR 201904207 T TR201904207 T TR 201904207T TR 201904207 T4 TR201904207 T4 TR 201904207T4
Authority
TR
Turkey
Prior art keywords
dendritic cells
compositions
preparation
mature dendritic
relates
Prior art date
Application number
TR2019/04207T
Other languages
English (en)
Inventor
J Schendel Dolores
Bigalke Iris
Zobywalski Anke
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt Gmbh filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt Gmbh
Publication of TR201904207T4 publication Critical patent/TR201904207T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Buluş en az bir olgun olmayan dendritik hücrenin in vitro mastürasyonu için bir yöntem ile ilişkilidir, b yöntem söz konusu olgun olmayan dendritik hücrenin TNF?, IL-1ß, IFNß, a TLR7/8 agonist ve prostaglandin E2 (PG) ile stimüle edilmesini içermektedir. Buna ilaveten, buluş söz konusu faktörleri içeren bir bileşim ile aynı zamanda da buluşun yöntemi ile üretilen olgun dendritik hücreler ile ilişkilidir.
TR2019/04207T 2006-03-28 2007-03-28 Olgun dendritik hücrelerin hazırlanması için bileşimler. TR201904207T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06006373A EP1840206A1 (en) 2006-03-28 2006-03-28 Compositions for the preparation of mature dendritic cells
US82582206P 2006-09-15 2006-09-15

Publications (1)

Publication Number Publication Date
TR201904207T4 true TR201904207T4 (tr) 2019-05-21

Family

ID=36441990

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04207T TR201904207T4 (tr) 2006-03-28 2007-03-28 Olgun dendritik hücrelerin hazırlanması için bileşimler.

Country Status (13)

Country Link
US (3) US8679840B2 (tr)
EP (4) EP1840206A1 (tr)
AU (1) AU2007229640B2 (tr)
CA (1) CA2647622C (tr)
CY (1) CY1121448T1 (tr)
DK (2) DK2918673T3 (tr)
ES (2) ES2535835T3 (tr)
HU (1) HUE042138T2 (tr)
PL (2) PL2918673T3 (tr)
PT (2) PT2004807E (tr)
SI (1) SI2918673T1 (tr)
TR (1) TR201904207T4 (tr)
WO (1) WO2007110240A1 (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1780220A1 (en) * 2005-11-01 2007-05-02 Charité - Universitätsmedizin Berlin Use of CEACAM8-specific substances for treating autoimmune diseases and a method for screening substances which induce apoptosis
WO2010049152A1 (en) * 2008-10-29 2010-05-06 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Novel composition for the preparation of mature dendritic cells
PL2534242T3 (pl) * 2010-02-10 2016-11-30 Polepszona kompozycja do hamowania proliferacji komórek nowotworowych
CN102933228A (zh) * 2010-03-15 2013-02-13 宾夕法尼亚大学董事会 制备和储存活化的、成熟树突细胞的体系和方法
EP2617434A1 (en) * 2012-01-20 2013-07-24 Laboratorios Del. Dr. Esteve, S.A. HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens
IN2014DN07961A (tr) * 2012-03-02 2015-05-01 Esteve Labor Dr
SI2913394T1 (sl) * 2012-12-18 2017-01-31 Immunicum Ab Ko-diferenciacija in aktivacija monocitov iz alogenskih darovalcev za zagotovitev proinflamatornih dendričnih celic
US20150335679A1 (en) * 2014-05-20 2015-11-26 Kiromic, Llc Methods and Compositions for Treating Malignancies with Dendritic Cells
BR112018000027A2 (pt) 2015-06-30 2022-09-06 Univ Nova De Lisboa População celular viável, método de produção e usos da mesma
MX2018007841A (es) * 2015-12-23 2018-11-09 Medigene Immunotherapies Gmbh Composicion de celula dendritica.
KR101946572B1 (ko) * 2017-01-31 2019-02-11 주식회사 큐라티스 면역 관용성 플라즈마사이토이드 수지상 세포 및 그 제조방법
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CA3074612C (en) * 2017-09-05 2022-08-30 Medigene Immunotherapies Gmbh Dendritic cell potency assay
SI3460052T1 (sl) * 2017-09-20 2020-03-31 Immunicum Ab Izboljšane alogene dendritične celice za uporabo pri zdravljenju raka
CN109182384A (zh) * 2018-09-30 2019-01-11 北京鼎成肽源生物技术有限公司 一种rff1细胞的构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
DK1441591T3 (en) * 2001-09-06 2017-05-22 Northwest Biotherapeutics Inc Compositions and Methods for Priming Monocytic Dendritic Cells and T-Cells for TH-1 Response
US20050003533A1 (en) * 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use

Also Published As

Publication number Publication date
EP2918673B1 (en) 2019-01-16
US20170037372A1 (en) 2017-02-09
US9512402B2 (en) 2016-12-06
ES2718525T3 (es) 2019-07-02
WO2007110240A1 (en) 2007-10-04
EP2004807B1 (en) 2015-03-04
CA2647622C (en) 2017-04-18
PT2918673T (pt) 2019-04-23
CY1121448T1 (el) 2020-05-29
HUE042138T2 (hu) 2019-06-28
EP2918673A1 (en) 2015-09-16
EP1840206A1 (en) 2007-10-03
PT2004807E (pt) 2015-05-20
US8679840B2 (en) 2014-03-25
US20140302096A1 (en) 2014-10-09
DK2918673T3 (en) 2019-04-01
CA2647622A1 (en) 2007-10-04
EP3517603A1 (en) 2019-07-31
EP2004807A1 (en) 2008-12-24
US20100284976A1 (en) 2010-11-11
ES2535835T3 (es) 2015-05-18
AU2007229640B2 (en) 2013-05-02
PL2918673T3 (pl) 2019-08-30
AU2007229640A1 (en) 2007-10-04
SI2918673T1 (sl) 2019-05-31
PL2004807T3 (pl) 2015-07-31
DK2004807T3 (en) 2015-05-11

Similar Documents

Publication Publication Date Title
TR201904207T4 (tr) Olgun dendritik hücrelerin hazırlanması için bileşimler.
RS54149B1 (en) COMPOSITIONS AND PROCEDURES IN VITRO AND IN VIVO, TARGETED MEDICINAL RELEASE IN Mammalian cells via intact minicells derived from bacteria
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
BRPI0714655B8 (pt) composição, e, kit
EA201070030A1 (ru) Синтез и применение антиинвертированных фосфоротиоатных аналогов кэп-структуры матричной phk
NZ610346A (en) Hyaluronic acid based formulations
ES2570382T3 (es) Composiciones y métodos para la producción de azúcares fermentables
MX2008001643A (es) Metodo para conservar la funcion de celulas productoras de insulina.
WO2010065876A3 (en) Methods and compositions related to th-1 dendritic cells
NO20082716L (no) Sammensetninger og fremgangsmater for fremstilling av en sammensetning
WO2009137624A3 (en) Hemangio colony forming cells and non-engrafting hemangio cells
AR054936A1 (es) Goma de mascar con pegajosidad reducida
MY157397A (en) Hard fat
BRPI0916936B8 (pt) composições farmacêuticas, uso de clevidipina e método de reduzir impurezas.
BRPI0519414A2 (pt) composiÇço oral, composiÇço em pasta ou gel, e, mÉtodos para inibir crescimento bacteriano na cavidade oral, e para manter saéde sistÊmica
TR201909466T4 (tr) Düşük serbest stearik asit içeren veya tespit edilebilen hiç serbest stearik asit içermeyen, stearik asitle işlenmiş kalsiyum karbonat bileşimleri ve ilgili yöntemler.
BRPI0514894A (pt) composições combustìveis
EP2585600A4 (en) REDUCTION OF THE CONTENT OF SATURATED FATTY ACIDS OF PLANT SEA
BRPI0514074A (pt) aperfeiçoamentos em composições em bloco para lavatório
UA91551C2 (ru) Композиция сложных алкиловых эфиров, способ ее получения и применения как биодизельного топлива
AR071743A1 (es) Metodo para preparar alcoxilatos de amidoamina y dichas composiciones
UA107487C2 (uk) Склад для профілактики кандидозів
TR201900996T4 (tr) Alçı sıva astarında veya selüloz eter içeren dolgu bileşimlerinde aglomerasyonu azaltma yöntemi.
EP2341147A3 (en) Preprimitive streak and mesendoderm cells
GB2457190A (en) Fischer-tropsch derived diesel fuel and process for making same